Literature DB >> 22334883

FDA rejects novel diabetes drug over safety fears.

Talha Khan Burki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22334883     DOI： 10.1016/s0140-6736(12)60216-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  16 in total

Review 1.  Glucose Control and Cardiovascular Outcomes in Clinical Trials of Sodium Glucose Co-transporter 2 Inhibitor Treatments in Type 2 Diabetes.

Authors:  Rene A Oliveros; Son V Pham; Steven R Bailey; Robert J Chilton
Journal:  Eur Endocrinol       Date:  2014-08-28

Review 2.  Cardiovascular safety profile of currently available diabetic drugs.

Authors:  Komola Azimova; Zinnia San Juan; Debabrata Mukherjee
Journal:  Ochsner J       Date:  2014

Review 3.  Dapagliflozin in patients with type 2 diabetes mellitus.

Authors:  Theodosios D Filippatos; Evangelos N Liberopoulos; Moses S Elisaf
Journal:  Ther Adv Endocrinol Metab       Date:  2015-02       Impact factor: 3.565

4.  Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease.

Authors:  Robert Klempfner; Jonathan Leor; Alexander Tenenbaum; Enrique Z Fisman; Ilan Goldenberg
Journal:  Cardiovasc Diabetol       Date:  2012-06-06       Impact factor: 9.951

Review 5.  Year in diabetes 2012: The diabetes tsunami.

Authors:  R Sherwin; A M Jastreboff
Journal:  J Clin Endocrinol Metab       Date:  2012-11-26       Impact factor: 5.958

6.  Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies.

Authors:  Samuel S Engel; Elizabeth Round; Gregory T Golm; Keith D Kaufman; Barry J Goldstein
Journal:  Diabetes Ther       Date:  2013-05-23       Impact factor: 2.945

7.  Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition.

Authors:  Resham Raj Poudel
Journal:  Indian J Endocrinol Metab       Date:  2013-07

Review 8.  What's next after metformin? focus on sulphonylurea: add-on or combination therapy.

Authors:  Phei C Lim; Chee P Chong
Journal:  Pharm Pract (Granada)       Date:  2015-06-15

9.  Validity of meta-analysis in diabetes: we need to be aware of its limitations.

Authors:  Philip D Home
Journal:  Diabetes Care       Date:  2013-10       Impact factor: 19.112

Review 10.  Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated.

Authors:  Brian K Irons; Molly G Minze
Journal:  Diabetes Metab Syndr Obes       Date:  2014-01-18       Impact factor: 3.168
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.